Targets and cross-reactivity of human T cell recognition of common cold coronaviruses

[1]  James J. Davis,et al.  Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR , 2022, Nucleic Acids Res..

[2]  A. Sette,et al.  Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic , 2022, Cell host & microbe.

[3]  A. West,et al.  Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models , 2022, Science.

[4]  A. Sette,et al.  Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors , 2022, International journal of molecular sciences.

[5]  P. Bjorkman,et al.  Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes , 2022, bioRxiv.

[6]  A. Sette,et al.  Inducing broad-based immunity against viruses with pandemic potential. , 2022, Immunity.

[7]  A. Sette,et al.  Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[8]  S. Gehring,et al.  Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2 , 2022, Frontiers in Immunology.

[9]  M. Killerby,et al.  Seasonality of Common Human Coronaviruses, United States, 2014–2021 , 2022, medRxiv.

[10]  A. Sette,et al.  Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period , 2022, bioRxiv.

[11]  M. Koopmans,et al.  Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.

[12]  A. Sette,et al.  Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status , 2022, Cell Host & Microbe.

[13]  A. Sette,et al.  Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant , 2022, Nature Medicine.

[14]  J. Derisi,et al.  Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function , 2022, JCI insight.

[15]  S. Mallal,et al.  SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron , 2022, Cell.

[16]  F. Noorbakhsh,et al.  SARS-CoV-2 spike protein displays sequence similarities with paramyxovirus surface proteins; a bioinformatics study , 2021, PloS one.

[17]  J. Sidney,et al.  A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. , 2021, Vaccine.

[18]  P. Gimotty,et al.  SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens , 2021, bioRxiv.

[19]  F. Krammer,et al.  Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination , 2021, Nature Communications.

[20]  A. Sette,et al.  Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine , 2021, Frontiers in Immunology.

[21]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[22]  S. Richardson,et al.  Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner , 2021, Cell Host & Microbe.

[23]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[24]  F. Balloux,et al.  Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection , 2021, medRxiv.

[25]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[26]  A. Wald,et al.  Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals , 2021, PLoS pathogens.

[27]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[28]  Julia Niessl,et al.  T cell immunity to SARS-CoV-2 , 2021, Seminars in Immunology.

[29]  M. Koopmans,et al.  SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.

[30]  Bjoern Peters,et al.  SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 , 2021, Cell Host & Microbe.

[31]  S. Prakash,et al.  Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines , 2021, The Journal of Immunology.

[32]  C. Szeto,et al.  CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses , 2021, Immunity.

[33]  Shibin Zhou,et al.  Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. , 2021, The Journal of clinical investigation.

[34]  K. Schnatbaum,et al.  Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.

[35]  A. Sette,et al.  Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers , 2021, The Journal of infectious diseases.

[36]  A. Sette,et al.  Pre-existing T Cell Memory against Zika Virus , 2021, Journal of Virology.

[37]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2021, Cell Reports Medicine.

[38]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[39]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[40]  Leo Swadling,et al.  Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection , 2020, Science Immunology.

[41]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[42]  C. Dutertre,et al.  Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , 2020, bioRxiv.

[43]  P. Rosenstiel,et al.  Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19 , 2020, Immunity.

[44]  M. Lipsitch,et al.  Cross-reactive memory T cells and herd immunity to SARS-CoV-2 , 2020, Nature Reviews Immunology.

[45]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[46]  H. Rammensee,et al.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.

[47]  N. Miller,et al.  Recent endemic coronavirus infection is associated with less severe COVID-19. , 2020, The Journal of clinical investigation.

[48]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[49]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[50]  H. Goossens,et al.  Seasonal coronavirus protective immunity is short-lasting , 2020, Nature Medicine.

[51]  P. Doherty,et al.  Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.

[52]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[53]  Bjoern Peters,et al.  Epitope prediction and identification- adaptive T cell responses in humans. , 2020, Seminars in immunology.

[54]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[55]  S. Mallal,et al.  Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination , 2020, Journal of Virology.

[56]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[57]  S. Perlman,et al.  Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.

[58]  A. Sette,et al.  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.

[59]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[60]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[61]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[62]  T. Schumacher,et al.  Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patients , 2020 .

[63]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[64]  L. Ferreira,et al.  CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection , 2020, Cell reports.

[65]  M. Chiarini,et al.  Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[66]  Sandeep Kumar Dhanda,et al.  Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy , 2020, Journal of immunology research.

[67]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[68]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[69]  Sandeep Kumar Dhanda,et al.  T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species , 2020, Journal of Virology.

[70]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[71]  M. Diamond,et al.  Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy , 2018, Nature Communications.

[72]  M. Diamond,et al.  Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy , 2018, Nature Communications.

[73]  Anne M Johnson,et al.  Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. , 2015, American journal of respiratory and critical care medicine.

[74]  J. Sidney,et al.  Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes , 2013, PLoS neglected tropical diseases.

[75]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[76]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[77]  J. Sidney,et al.  Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. , 2010, Human immunology.

[78]  John Sidney,et al.  Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans , 2008, Journal of Virology.

[79]  P. Masters,et al.  The Molecular Biology of Coronaviruses , 2006, Advances in Virus Research.

[80]  John Sidney,et al.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.

[81]  John Sidney,et al.  Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes , 2001, Journal of Virology.

[82]  John Sidney,et al.  HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles1 2 , 2000, The Journal of Immunology.

[83]  W. R. Dowdle,et al.  Coronaviridae , 1990, Virus Infections of Ruminants.

[84]  M. Oudshoorn,et al.  Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. , 1996, Human immunology.